ClinicalTrials.gg
RecruitingNCT07409142Updated Feb 20, 2026

BetterLife FSHD: A Patient-driven Health and Research Platform

An observational study in FSH, FSH Muscular Dystrophy and FSHD - Facioscapulohumeral Muscular Dystrophy, sponsored by FSHD Society. Recruiting at 1 site in United States. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by FSHD Society · Observational

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States — 8 open to participants now, 13 under way, 1 of them phase 3. Muscular Dystrophy, Facioscapulohumeral · United States.

Planned enrollment
2nd of 11
5,000 · median 94
Started
2024
with 1 other
Observational
11 of 32
4 open now
Primary completion
2060-01
later than 12 of 12 live
Registered
27th of 32
by date
Lead sponsor
1 of 32
FSHD Society

Among the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, this one is the 2nd largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2024, is one of 11 observational ones, reaches primary completion later than 12 of the 12 other live ones, and was the 27th registered.

Muscular Dystrophy, Facioscapulohumeral

79 studies on the registry are indexed under Muscular Dystrophy, Facioscapulohumeral; 26 are open to participants now.

Browse Muscular Dystrophy, Facioscapulohumeral studies →

Open to participants now

8 of the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Muscular Dystrophy, Facioscapulohumeral studies recruiting now, 9 (47%) set no upper age limit and 9 (47%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, or all of them as a file.
02

Study summary

BetterLife FSHD is a registry platform built to support people living with FSHD. It connects patients with personalized resources, tools, and research opportunities that match their health experiences and needs. At the same time, BetterLife collects secure health and experience data from patients to support research. This data is shared with researchers to help better understand FSHD and work toward improved care, treatments, and outcomes for the community.

Learn more and enroll at: www.BetterLifeFSHD.org

Read the detailed description

Facioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder that causes relentless weakening of skeletal muscles. BetterLife FSHD is a patient-driven health platform and research registry that aims to help FSHD patients live their best lives while also powering research.

In BetterLife, participants are prompted to respond to a series of short surveys spread out over a quarterly and yearly basis. Survey topics include demographics, health history, FSHD diagnosis and progression, FSHD management strategies, and quality of life domains like pain, fatigue, and mental health.

As participants provide survey data, they receive a personalized feed of resources relevant to them from the FSHD Society's library of articles, blogs, videos, and webinars. Survey data is also used to inform participants which clinical trials and other research studies they may be eligible for.

The information that BetterLife FSHD collects is stored and managed in a modern and secure real-world data infrastructure. De-identified data is made available upon request to researchers, clinicians, biopharmaceutical companies, regulator/payor bodies, and other organizations involved in FSHD research and therapeutic development with approval from a steering committee. BetterLife can also be used to conduct and support research initiatives external to the FSHD Society.

03

Conditions studied

  • FSH
  • FSH Muscular Dystrophy
  • FSHD - Facioscapulohumeral Muscular Dystrophy
  • FSHD1
  • FSHD
  • FSHD2
  • Facioscapulohumeral Muscular Dystrophy
  • Facioscapulohumeral Muscular Dystrophy 1
  • Facioscapulohumeral Muscular Dystrophy 2
  • Facioscapulohumeral Muscular Dystrophy (FSHD)
  • Muscular Dystrophy, Facioscapulohumeral

Keywords

  • FSHD
  • Registry
  • FSH Muscular Dystrophy
  • FSHD1
  • FSHD2
  • Facioscapulohumeral dystrophy
  • facioscapulohumeral muscular dystrophy
04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People with FSHD living in the United States or its territories age one year or older.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with a clinical or genetic diagnosis of FSHD, or individuals with a family history of FSHD who are showing symptoms
  • Age 1 year or older
  • Residing in the United States or its territories
  • If age 18 or older, individual must be able and willing to provide consent
  • If under age 18, individual must be able and willing to provide assent, when applicable, and have a parent or legal guardian register and provide consent

Exclusion criteria

Exclusion Criteria:

  • Individuals residing outside the United States or its territories
  • Unable or unwilling to provide consent, or assent, when applicable
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Target follow-up
100 Years
Patient registry
Yes

Interventions

  • OtherObservational

    Observational study

06

What researchers measure

Primary outcomes

  1. Longitudinal Health Data

    Survey questions to capture information on demographics, health history, FSHD diagnosis (clinical diagnosis, genetic testing, family history, etc.), and FSHD symptom management (e.g., use of assistive devices, ventilation, surgery).

    Time frame: Assessed annually from enrollment until study completion (10 years)

  2. Self Reported FSHD Progression

    Survey questions that cover muscle weakness, symptom onset, and key progression milestones, and which can be used to estimate FSHD Clinical Score (FCS) . A higher score indicates more disease severity.

    Time frame: Assessed every 6 months, until study completion (10 years)

Secondary outcomes

  1. Anxiety Patient Reported Outcome Measure

    Assesses frequency and impact of anxiety symptoms using a 5-point rating system. Higher scores indicate more anxiety.

    Time frame: Quarterly, until study completion (10 years)

  2. Depression Patient Reported Outcome Measure

    Assesses frequency and impact of depression symptoms using a 5-point rating system. Higher scores indicate more depression.

    Time frame: Quarterly, until study completion (10 years)

  3. Pain Patient Reported Outcome Measure

    Assesses the quality of pain and interference with daily life using a 5-point rating system. Higher scores indicate higher levels of pain and interference.

    Time frame: Quarterly, until study completion (10 years)

  4. Sleep Patient Reported Outcome Measure

    Assesses the quality of sleep using a 5-point rating system. Higher scores indicate poor sleep quality.

    Time frame: Quarterly, until study completion (10 years)

  5. Fatigue Patient Reported Outcome Measure

    Assesses the presence and severity of fatigue using a 5-point rating system. Higher scores indicate more fatigue.

    Time frame: Quarterly, until study completion (10 years)

  6. Upper Body Patient Reported Outcome Measure

    Assesses the ability to perform activities of daily living with the upper body using a 5-point rating system. Higher scores indicate less difficulty completing tasks using the upper body.

    Time frame: Quarterly, until study completion (10 years)

  7. Mobility Patient Reported Outcome Measure

    Assesses the ability to perform activities with the lower body (i.e., standing up, sitting) using a 5-point rating system. Higher scores indicate less difficulty using the lower body.

    Time frame: Quarterly, until study completion (10 years)

  8. Physical Activity Patient Reported Outcome Measure

    Assesses the amount of time spent engaged in physical activity in minutes. Higher scores indicate greater levels of physical activity.

    Time frame: Quarterly, until study completion (10 years)

  9. Falls Patient Reported Outcome Measure

    Assesses fear of falling during daily activities using a 4-point scale. Higher scores indicate a greater fear of falling.

    Time frame: Quarterly, until study completion (10 years)

  10. Research Preferences

    Survey questions where participants rank their willingness to participate in various research procedures, concerns about participating in research trials, and preferences for remote/in-person/hybrid study visits.

    Time frame: Yearly until study completion (10 years)

  11. Diagnostic Journey

    Survey questions to describe participant experience and barriers getting diagnosed with FSHD.

    Time frame: One time at Baseline

  12. Healthcare Experiences

    Survey questions to describe healthcare utilization and experiences navigating healthcare settings.

    Time frame: Yearly, until study completion (10 years)

  13. Women's Health

    Survey questions about history of menstruation and pregnancy.

    Time frame: Yearly, until study completion (10 years)

  14. Social Determinants of Health

    Survey questions about current employment status/job security, neighborhood, religious practices, discrimination, and food security.

    Time frame: Yearly, until study completion (10 years)

07

Study locations

1 of 1 sites recruiting
  • FSHD Society
    Randolph, Massachusetts 02368, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All individual participant data (IPD) collected by BetterLife is made available to the research community in the form of de-identified or limited datasets upon request and approval by the Steering Committee.

Supporting information: Study protocol, Informed consent form

Time frame: IPD and supporting information were available beginning August 2024 and with no planned end date.

Access criteria: Researchers can request access IPD and supporting information. Researchers may include pharmaceutical or biotechnology companies, academic institutions, hospitals, or other organizations involved in research and therapeutic development. Government agencies or payor systems who make decisions about treatment approvals and access, for example, the Food and Drug Administration (FDA) or the Institute for Clinical and Economic Review (ICER) can also request access. To request access, researchers should visit www.BetterLifeFSHD.org or email BetterLife@FSHDSociety.org. Researchers must provide key details about their research project, including PI and study contacts, brief background information, clear study objectives, procedures, and outcomes, summary of importance for the field, and documentation of IRB approval, when required. All requests are reviewed by the Steering Committee. Projects that are approved must agree to a data use agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Jan 2060, 425 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Feb 13, 2026
StartActual
Aug 2, 2024
Primary completionEst.
Jan 2060
CompletionEst.
Jan 2060
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07409142
Lead sponsor
FSHD Society
Responsible party
Amanda Hill (Senior Director of Research, FSHD Society) — Principal investigator
First posted
Feb 13, 2026
Start date
Aug 2, 2024
Primary completion
Jan 2060 (estimated)
Completion
Jan 2060 (estimated)
Last update
Feb 20, 2026

Study contacts

Kayleigh Worek, MS
Contact
betterlife@fshdsociety.org
781-301-6060 ext. 2900
Amanda Hill, MBA
principal investigator · FSHD Society

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion